190 related articles for article (PubMed ID: 10211421)
1. Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis.
Wang X; Sun Z; Börjesson A; Haraldsen P; Aldman M; Deng X; Leveau P; Andersson R
Int J Pancreatol; 1999 Feb; 25(1):45-52. PubMed ID: 10211421
[TBL] [Abstract][Full Text] [Related]
2. Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant.
Leveau P; Wang X; Sun Z; Börjesson A; Andersson E; Andersson R
Biochem Pharmacol; 2005 May; 69(9):1325-31. PubMed ID: 15826603
[TBL] [Abstract][Full Text] [Related]
3. Effect of a platelet-activating factor antagonist on pancreatitis-associated gut barrier dysfunction in rats.
Andersson R; Wang X; Sun Z; Deng X; Soltesz V; Ihse I
Pancreas; 1998 Aug; 17(2):107-19. PubMed ID: 9700940
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet-activating factor, intercellular adhesion molecule 1 and platelet endothelial cell adhesion molecule 1 reduces experimental pancreatitis-associated gut endothelial barrier dysfunction.
Wang X; Sun Z; Börjesson A; Andersson R
Br J Surg; 1999 Mar; 86(3):411-6. PubMed ID: 10201790
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment of gut barrier dysfunction using an antioxidant, a PAF inhibitor, and monoclonal antibodies against the adhesion molecule PECAM-1.
Sun Z; Olanders K; Lasson A; Dib M; Annborn M; Andersson K; Wang X; Andersson R
J Surg Res; 2002 Jun; 105(2):220-33. PubMed ID: 12121711
[TBL] [Abstract][Full Text] [Related]
6. Effects of inhibition of PAF, ICAM-1 and PECAM-1 on gut barrier failure caused by intestinal ischemia and reperfusion.
Sun Z; Wang X; Lasson A; Böjesson A; Annborn M; Andersson R
Scand J Gastroenterol; 2001 Jan; 36(1):55-65. PubMed ID: 11218240
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of lexipafant, a PAF antagonist on gut barrier dysfunction caused by intestinal ischemia and reperfusion in rats.
Sun Z; Wang X; Deng X; Lasson A; Soltesz V; Börjesson A; Andersson R
Dig Surg; 2000; 17(1):57-65. PubMed ID: 10720833
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating factor.
Kingsnorth AN
Scand J Gastroenterol Suppl; 1996; 219():28-31. PubMed ID: 8865468
[TBL] [Abstract][Full Text] [Related]
9. Multimodal management - of value in fulminant acute pancreatitis?
Haraldsen P; Sun ZW; Börjesson A; Olanders K; Lasson A; Andersson R
Pancreatology; 2003; 3(1):14-25. PubMed ID: 12649560
[TBL] [Abstract][Full Text] [Related]
10. Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis.
Lane JS; Todd KE; Gloor B; Chandler CF; Kau AW; Ashley SW; Reber HA; McFadden DW
J Surg Res; 2001 Aug; 99(2):365-70. PubMed ID: 11469912
[TBL] [Abstract][Full Text] [Related]
11. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.
Johnson CD; Kingsnorth AN; Imrie CW; McMahon MJ; Neoptolemos JP; McKay C; Toh SK; Skaife P; Leeder PC; Wilson P; Larvin M; Curtis LD
Gut; 2001 Jan; 48(1):62-9. PubMed ID: 11115824
[TBL] [Abstract][Full Text] [Related]
12. Early treatment with lexipafant, a platelet-activating factor-receptor antagonist, is not sufficient to prevent pulmonary endothelial damage after intestinal ischaemia and reperfusion in rats.
Börjesson A; Wang X; Sun Z; Inghammar M; Truedsson L; Andersson R
Dig Liver Dis; 2002 Mar; 34(3):190-6. PubMed ID: 11990391
[TBL] [Abstract][Full Text] [Related]
13. The use of lexipafant in the treatment of acute pancreatitis.
McKay C; Curran FJ; Sharples CE; Young CA; Baxter JN; Imrie CW
Adv Exp Med Biol; 1996; 416():365-70. PubMed ID: 9131175
[TBL] [Abstract][Full Text] [Related]
14. Lexipafant fails to improve survival in severe necrotizing pancreatitis in rats.
Rivera JA; Werner J; Warshaw AL; Lewandrowski KB; Rattner DW; Fernández del Castillo C
Int J Pancreatol; 1998 Apr; 23(2):101-6. PubMed ID: 9629507
[TBL] [Abstract][Full Text] [Related]
15. Mast cells contribute to early pancreatitis-induced systemic endothelial barrier dysfunction.
Dib M; Zhao X; Wang X; Andersson R
Pancreatology; 2002; 2(4):396-401. PubMed ID: 12138228
[TBL] [Abstract][Full Text] [Related]
16. Effect of platelet-activating factor antagonist WEB 2086 on microcirculatory disorders in acute experimental pancreatitis of graded severity.
Mann O; Tiefenbacher WJ; Kaifi J; Schneider C; Kluth D; Bloechle C; Yekebas E; Izbicki JR; Strate T
Pancreas; 2009 Jan; 38(1):58-64. PubMed ID: 18695628
[TBL] [Abstract][Full Text] [Related]
17. Everolimus Improves Microcirculatory Derangements in Experimental Postischemic Pancreatitis Modulating the Expression of Vascular Endothelial Growth Factor, Interleukin 6, and Toll-Like Receptor 4.
Meyer S; Neeff H; Thomusch O; Strate T; Tittelbach-Helmrich D; Hopt UT; von Dobschuetz E
Pancreas; 2015 Nov; 44(8):1245-51. PubMed ID: 26390417
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor blockade in severe acute pancreatitis leads to systemic enhancement of microcirculation, stabilization of capillary permeability, and improved survival rates.
Foitzik T; Eibl G; Hotz HG; Faulhaber J; Kirchengast M; Buhr HJ
Surgery; 2000 Sep; 128(3):399-407. PubMed ID: 10965310
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis.
Kingsnorth AN; Galloway SW; Formela LJ
Br J Surg; 1995 Oct; 82(10):1414-20. PubMed ID: 7489182
[TBL] [Abstract][Full Text] [Related]
20. Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis.
Curtis LD
Adv Exp Med Biol; 1996; 416():361-3. PubMed ID: 9131174
[No Abstract] [Full Text] [Related]
[Next] [New Search]
